Bayer has announced plans to invest 2.2 billion USD in a new pharmaceutical manufacturing site in New Albany, Ohio, United States, as the company expands its pharmaceutical manufacturing capabilities and strengthens its presence in the U.S. market.
The planned facility will be located at the New Albany International Business Park and is expected to create around 600 high-value jobs once operational. Bayer also estimates that approximately 1,500 construction jobs will be generated during the development of the facility.
New Manufacturing Campus to Be Built in Phases
According to Bayer, the new facility will be developed as a flexible, modular manufacturing campus combining drug substance and drug product manufacturing.
The site will use advanced digital technologies and automation and will initially support Bayer's growing pharmaceutical portfolio in areas including oncology, cardiovascular diseases and renal care.
The first module, focused on drug substance manufacturing, is expected to become operational in 2031. A second module dedicated to drug product manufacturing is planned to follow in 2034.
Bayer Has Already Invested More Than 7 Billion USD in U.S. Pharma
The Ohio project builds on Bayer's substantial investment in the United States. The company said it has spent more than 7 billion USD on pharmaceutical R&D and manufacturing in the U.S. over the past five years.
Bayer described the new investment as an important part of its long-term growth strategy and its efforts to strengthen patient access and pharmaceutical production in its largest pharmaceutical market.
Why Ohio?
The new manufacturing site is expected to strengthen Bayer's U.S. supply network and improve the company's ability to manufacture and supply medicines for patients in the United States and other markets.
Bayer said the Ohio facility will complement its existing U.S. pharmaceutical operations, including its headquarters in Whippany, New Jersey, along with sites in Pennsylvania, California, Massachusetts and North Carolina.
The company also plans to develop a U.S.-based collaboration ecosystem around the new site, connecting academic innovation with advanced pharmaceutical manufacturing expertise.
Bayer Strengthens U.S. Pharmaceutical Strategy
Sebastian Guth, Global Chief Operating Officer of Bayer Pharmaceuticals and President of Bayer U.S., said the United States is a key market for Bayer's Pharmaceuticals division and described the expansion as an important step toward meeting demand from patients and customers in the U.S. and internationally.
Bayer's planned Ohio investment therefore represents not only an expansion of manufacturing capacity but also a long-term commitment to pharmaceutical production, technology and skilled employment in the United States.
